Pfizer pill reduces progression by 81% for a rare type of lung cancer

60% of patients who received Lorbrena were alive and had not seen their tumors progress in the five years of a study presented at ASCO.

May 31, 2024 Check out STAT+

Sponsored By

AP/Business Wire STAT+ | For one rare type of lung cancer, Pfizer pill reduces progression by 81% It's a stunning number, especially considering that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug. By Matthew Herper What the rescheduling of marijuana might — and might not — mean for scientific research Cannabis use is soaring but medical research on health effects is lagging. Would a Schedule III designation ease research burdens? By Nicholas Florko and Sarah Owermohle STAT+ | Many docs who tweeted product endorsements also took money from manufacturers, analysis shows A new study found 93% of doctors who tweeted about a drug or device received at least one payment from the product's manufacturer. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser